The FDA's Oncologic Drugs Advisory Committee Will Likely Vote Against Novartis' Panobinostat

The FDA's Oncologic Drugs Advisory Committee Will Likely Vote Against Novartis' Panobinostat

Submitted by admin on November 6, 2014 - 9:47am
Source: 
Seeking Alpha
News Tags: 
FDA
advisory panels
Novartis
panobinostat
Multiple Myeloma
Headline: 
The FDA's Oncologic Drugs Advisory Committee Will Likely Vote Against Novartis' Panobinostat

Do Not Allow Advertisers to Use My Personal information